All News
RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)
Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.
Read Article
ICYMI: Dactylitis Indicates a Severe PsA Phenotype
https://t.co/7VVoc0f1Ap https://t.co/uZxfqLvtcp
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: 520 RA pts were screened with FibroScan (liver fibrosis)- F3 or F4 liver fibrosis seen 13.3% of controls vs 12.7% arthritis pts. MTX was not significantly correlated w/ higher FS scores. Liver stiffness was correlated w/ BMI, waist, male , age. https://t.co/PxrabHROPy https://t.co/UAw51Hb5vU
Links:
Dr. John Cush RheumNow ( View Tweet)
Humbled to lecture at the #StaabSymposium with rheum greats @RheumNow and @KeithReich3 https://t.co/RHM1oneIc3
TheDaoIndex KDAO2011 ( View Tweet)
What I learned... always get an ALP and phosphorus level in people with chronic bony pain. https://t.co/nE0xYwODmC
TheDaoIndex KDAO2011 ( View Tweet)
Useful TST (PPD)/IGRA interpreter website for TB testing. A 31 yoM Texan w/ +IGRA only (true pos) has risk of active TB & INH hepatitis 0.1% & 0.4%. But if this was 60 yoF from Iraq on TNFi & pred the same risks are 20% & 2.3% https://t.co/M18cHuLrXu https://t.co/zIoFY4abXN
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Metanlysis of psychological interventions for chronic low back pain (97 RCTs, 13,136 pts) finds that Only behavioural therapy delivered w/ physiotherapy care (mainly structured exercise) reduced pain intensity up (high quality evidence) https://t.co/56pMRVk0ic https://t.co/wxcfninf14
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Review of 5 trials shows ixekizumab with higher rates of complete skin & nail clearance compared H2H against to etanercept, guselkumab, ustekinumab, and adalimumab (Data from IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, & SPIRIT-H2H trials https://t.co/t5wrmE3nbK #PsA #PsAlways https://t.co/MQjgktOZWR
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty. #PsAlways https://t.co/gHmZs3SW9S
Dr. John Cush RheumNow ( View Tweet)
Join us on April 12th for Tuesday Night Rheumatology at 7pm ET.
This week will host a conversation between Dr. Cush and Dr. Artie Kavanaugh on PsA medical journal articles.
Register today: https://t.co/YQD598xt7X https://t.co/k5uDeojEh7
Links:
Dr. John Cush RheumNow ( View Tweet)
Depression was studied in 208 #PSA patients - Depression was found in 30%. Depression risk was higher in those with higher disease activity (DAPSA; P=.007) and functional impairment (HAQ-DI; p=-.02) https://t.co/0bZ2xPprTp https://t.co/Gdiic5iKCi
Links:
Dr. John Cush RheumNow ( View Tweet)
Survey Question for RHEUMATOLOGISTS ONLY - Glucocorticoids are only used in #PsA under what circumstance? ANSWER here>> https://t.co/lqdZilbogR https://t.co/XxnOu9cQk3
Links:
Dr. John Cush RheumNow ( View Tweet)
I signed up for a great LUPUS Symposia on Saturday May 7th. Its all about the future of #SLE! You should register. Check out the all-start faculty! Drs. Chakravarty, Clowse, Costenbader, Furie, James, Kalunian, Kim, Merrill, Mohan, Pascual, Petri https://t.co/eZIJoEEzo9 https://t.co/09Da4kEUUF
Links:
Dr. John Cush RheumNow ( View Tweet)
CorEvitas Registry study of Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted in modest, nonsignificant improvement axial outcomes,(irrespective HLA-B27 status), including ASDAS40, BASDAI50, & spinal pain. 31% of pts were B27+ https://t.co/9m9H7PwIIF #PsAlways https://t.co/dYk5GfIdez
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has granted a Priority Review for tocilizumab (Actemra) intravenous for the treatment of hospitalised COVID-19 adults receiving systemic corticosteroids and require supplemental O2, mechanical ventilation, or ECMO. https://t.co/b4GSuvsElp https://t.co/oEGskAJVyd
Links:
Dr. John Cush RheumNow ( View Tweet)
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/Hc4rNrlQzP https://t.co/UPosZIc4C0
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/0nvutsXHsI https://t.co/jh43zCbdZx
Links:
Dr. John Cush RheumNow ( View Tweet)
Differences between Palpated & Ultrasound Joint exams in 155 #PSA patients. 5616 joints - found 18.5% tender, 9.8% swollen, 20.4% w/ US GS ≥ 2 and 5.2% had US PD ≥ 1. Joints that were both tender and swollen more likely to have GS ≥ (44%) https://t.co/nWI7jLdkWp https://t.co/iRNsqWYScM
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheum Comanagement of Psoriasis
https://t.co/vXF4t2IIoW
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/fDVx49XtYP
Links:
Dr. John Cush RheumNow ( View Tweet)
“Do as much as possible for the patient, & as little as possible to the patient.” (B Lown). JAMA review of Antithrombotics in COVID-19 says all hospitalized COVID pts with COVID-19 should recv anticoagulation with heparin; no proven value to anti-Plts Rx https://t.co/ZfaH4FiRy1 https://t.co/DW8BGKjfnX
Links:
Dr. John Cush RheumNow ( View Tweet)